Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 46.58B | 46.61B | 47.64B | 50.74B | 44.08B | 41.40B |
Gross Profit | 25.15B | 25.34B | 27.89B | 30.87B | 27.27B | 22.26B |
EBITDA | 8.08B | 8.81B | 4.21B | 10.44B | 6.97B | -11.48B |
Net Income | -3.25B | -2.55B | -2.94B | 4.15B | 1.00B | -15.56B |
Balance Sheet | ||||||
Total Assets | 109.18B | 110.85B | 116.26B | 124.88B | 120.24B | 117.05B |
Cash, Cash Equivalents and Short-Term Investments | 5.38B | 8.09B | 10.59B | 10.15B | 7.74B | 11.88B |
Total Debt | 39.38B | 40.81B | 44.79B | 41.32B | 39.53B | 41.55B |
Total Liabilities | 76.60B | 78.81B | 83.18B | 85.95B | 87.07B | 86.35B |
Stockholders Equity | 32.45B | 31.91B | 32.93B | 38.77B | 33.02B | 30.52B |
Cash Flow | ||||||
Free Cash Flow | 5.27B | 4.59B | 2.37B | 4.14B | 2.48B | 2.48B |
Operating Cash Flow | 7.99B | 7.37B | 5.12B | 7.09B | 5.09B | 4.90B |
Investing Cash Flow | 22.00M | 164.00M | -4.01B | -2.38B | 855.00M | -4.07B |
Financing Cash Flow | -9.10B | -7.18B | -679.00M | -4.22B | -5.64B | 423.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
62 Neutral | €26.50B | ― | -9.56% | 0.36% | -0.92% | -4.30% | |
46 Neutral | C$190.36M | -4.25 | -8.56% | 3.09% | 13.53% | -1.76% | |
€14.17B | 22.92 | 4.37% | 2.98% | ― | ― | ||
€23.75B | 56.85 | 6.28% | 2.04% | ― | ― | ||
€48.98B | 17.38 | 9.74% | 1.97% | ― | ― | ||
€13.80B | 127.95 | 3.55% | 0.41% | ― | ― | ||
$61.33B | 27.38 | 11.14% | 1.80% | ― | ― |
Bayer Aktiengesellschaft announced a transaction involving the purchase of shares by a member of its supervisory board, Kimberly Mathisen. This transaction, conducted at the Frankfurt Stock Exchange, reflects the board members’ commitment to buy Bayer AG shares, potentially signaling confidence in the company’s future performance.